Value Creation Story

History of Value Creation

2021 –
Aim for further growth

Since our founding in 1920 as a pioneer in hormone preparations, we have unerringly continued on

ASKA Pharmaceutical Holdings’ Medium-Term Management
Plan 2025 was launched in 2021. In conjunction with theshift to a holding company structure, the Company not only
aims to build a flexible organization that is capable of swift
decision-making, but also to achieve further sustainablegrowth for the entire Group by further strengthening its
governance structure.

our journey, while always keeping in mind our essential mission as a company that is directly linked
to life and health. In 2021, we transitioned to a holding company structure, and took a new step
toward the next 100 years. We will continue to respond to the changing times and environment,

2005 – 2021

and contribute to society as we evolve into a total healthcare company.

Formation of ASKA Pharmaceutical Co., Ltd.

1955 – 2005

Became a company that makes
wide-ranging contributions to society

1920 – 1955

After the postwar reconstruction period, the company worked
to modernize its management through organizational reforms,
expansion of its sales and production systems, reorganizationof its research functions, and reinforcement of its advertising
activities. In addition to entering the field of veterinary
pharmaceuticals, the company also strived to diversify its
business and worked toward corporate growth in the midst ofan era of rapid economic growth.

Took our first step as a pharmaceutical company
In 1920, Yasohachi Yamaguchi established Teikoku Hormone
Research Institute. It began the research, development,
manufacture and sales of hormone preparations based on theunique idea of creating useful medicines from animal organs.
Although the company experienced hardships such as theGreat Kanto Earthquake, and the loss of its head office andfactory during the Second World War, it was rebuilt under anew organizational structure, and listed its shares on theTokyo Stock Exchange in 1955.
Launched in 1921
Male gonadal hormone agent

Launched in 1922
Hypothyroidism agent

SPERMATINTHYRADIN

Launched in 1981
Benign prostatic hyperplasia
and prostate cancer agent

In 2005, ASKA Pharmaceutical Co., Ltd. was established to develop
and market new drugs, specializing in the three priority areas of internal
medicine, obstetrics and gynecology (Ob/Gyn), and urology with theaim of becoming a competitive specialty pharma company. The company
took on challenges for the next stage, such as strengthening efforts
for generic drugs that meet the needs of the times.
Launched in 2011
Hyperlipidemic agent

Launched in 2014
Antihypertensive agent

Launched in 2016
Hepatic encephalopathy agent

LIPIDILCANDESARTAN “ASKA”

RIFXIMA

Launched in 2014
Endometriosis, uterine fibroids,and prostate cancer agent

Launched in 2016
Infertility agent

Launched in 2018
Dysmenorrhea agent

LUTEUM

FREWELL “ASKA”

LEUPRORELIN “ASKA”

Launched in 1986
Gastritis and gastric ulcer agent

Launched in 2019
Uterine fibroids andendometriosis agent

FY2022RELUMINA¥60,461 million

2022

Launched in 2021
Hair hormone levelmeasurement kit

Dihydrotestosterone

Launched in 2021
Feline hyperthyroidism agent

THYLOBLOCK

Enforcement of Revised
Act on the Promotionof Women’s Active
Engagement inProfessional Life

45,849ALTATPROSTAL1986

Launched in 1999
Low-dose oral contraceptive

ANGE

2016

Enforcement ofEqual Employment
Opportunity Act

Launched in 1926
Posterior pituitary hormone agent

24,3901975

ATONIN23,537

Enforcement of Act onthe Promotion of Women’s
Active Engagementin Professional LifeInternational
Women’s Year

Launched in 2022
Canine hyperadrenocorticism agent

Trilostane tablet “ASKA”

1945

12,409

Women’s suffragein Japan

1992
4,929

Net sales (Millions of yen)

(FY)

1920

Line item
Fiscal year-end

6

ASKA HD REPORT 2023

0.038

4.115

294

1929

1940

1950

Sales profit
Six-month settlement period(Two six-month periods were combined
for the data for years 1930-1937)

Product proceeds

Eight-monthsettlement period

Product proceeds
Twenty-four-monthsettlement period

Launched in 2022
Dysmenorrhea agent

Enforcement ofChildcare Leave Act*

940

DroEthi “ASKA”

Launched in 2023
Hair and nail stresshormone level test kit

Cortisol*C urrently Act on Childcare
Leave/Caregiver Leave

1960

1970

1980

1990

Net sales
Ten-month settlement period

2000

2010

2020

Net sales
Six-month settlement period

Consolidated accounting(Merged with Grelan Pharmaceutical Co., Ltd. in October 2005)

Four-month settlement period
ASKA HD REPORT 2023

7